Pancreatic cancer: FDA approves Optune Pax wearable device
The FDA has approved Optune Pax, a wearable device that delivers electric fields for inoperable, locally advanced pancreatic cancer; clinical trial results reported roughly a two-month average survival benefit and a delay in pain.
